iclusig.se
After failure of one 2nd generation TKI move to the 3rd generation:
Iclusig® (ponatinib) the most
potent BCR-ABL TKI approved1
Fast response
Deep response
Durable response
Median time to MCyR in CP-CML
responders: 2.8 months (84 days)2,3
38 % of CP-CML patients
reached MMR2 or even
deeper response (MR4.5)3
87 % of CP-CML responders
maintained MCyR at 24 months
(Kaplan-Meier estimate)2
Median time to MMR in CP-CML
responders: 5.5 months (168 days)2
